Deutsche Bank AG reaffirmed their buy rating on shares of Shire PLC (LON:SHP) in a research note released on Monday morning. They currently have a GBX 6,000 ($78.32) target price on the biopharmaceutical company’s stock.

SHP has been the topic of a number of other research reports. Royal Bank Of Canada reissued an outperform rating on shares of Shire PLC in a research report on Wednesday, June 15th. JPMorgan Chase & Co. reissued an overweight rating and set a GBX 6,300 ($82.23) price objective (up previously from GBX 5,600 ($73.10)) on shares of Shire PLC in a research report on Monday, August 1st. Jefferies Group increased their price objective on shares of Shire PLC from GBX 6,050 ($78.97) to GBX 6,600 ($86.15) and gave the stock a buy rating in a research report on Wednesday, August 3rd. Morgan Stanley reissued an overweight rating and set a GBX 5,600 ($73.10) price objective on shares of Shire PLC in a research report on Friday, June 3rd. Finally, Shore Capital reissued a buy rating on shares of Shire PLC in a research report on Tuesday, June 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus target price of GBX 5,841.33 ($76.25).

Shire PLC (LON:SHP) opened at 5278.00 on Monday. The firm’s 50-day moving average price is GBX 4,955.75 and its 200-day moving average price is GBX 4,434.49. The firm’s market cap is GBX 36.04 billion. Shire PLC has a 12 month low of GBX 2,707.19 and a 12 month high of GBX 5,300.00.

The company also recently declared a dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 8th will be issued a GBX 3.51 ($0.05) dividend. This represents a yield of 0.07%. The ex-dividend date is Thursday, September 8th.

In other news, insider Bohuon,Olivier purchased 134 shares of the business’s stock in a transaction on Thursday, June 30th. The stock was purchased at an average cost of GBX 4,463 ($58.26) per share, with a total value of £5,980.42 ($7,806.32).

About Shire PLC

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.